Investors Press Releases Jan 10 2025 Tiziana Announces Reduction of Side Effects Commonly Seen with Discontinuation of GLP-1 Agonists with Nasal Anti-CD3 Read More Jan 08 2025 Tiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological Disease Read More Dec 17 2024 Tiziana Life Sciences Announces First Patient with Moderate Alzheimer’s Disease Dosed with Intranasal Foralumab Read More btn News View All Events & Presentations Dec 12 2024 at 8:30 AM EST Dec 12 2024 at 8:30 AM EST Annual General Meeting 2024 Read More Dec 14 2023 at 8:30 AM EST Dec 14 2023 at 8:30 AM EST Annual General Meeting 2023 Read More Jun 05 2023 at 12:30 PM EDT Jun 05 2023 at 12:30 PM EDT Tiziana Life Sciences: Foralumab Update in Non-Active Secondary Progressive Multiple Sclerosis (na SPMS) Read More btn Events View All Interim Reports Interim Results for the Six Months Ended 30 June 2024 629.8 KB bth Interim Reports View All Annual Reports 20 F - Annual Report for the year ended 31 December 2023 8.9 MB btn ARs View All Annual General Meeting 2024 AGM Results 106.7 KB btn AGM View All Stock Quote Change Volume Today's Open Previous Close Today's High Today's Low 52 Week High 52 Week Low Stock Chart
Jan 10 2025 Tiziana Announces Reduction of Side Effects Commonly Seen with Discontinuation of GLP-1 Agonists with Nasal Anti-CD3 Read More
Jan 08 2025 Tiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological Disease Read More
Dec 17 2024 Tiziana Life Sciences Announces First Patient with Moderate Alzheimer’s Disease Dosed with Intranasal Foralumab Read More
Jun 05 2023 at 12:30 PM EDT Jun 05 2023 at 12:30 PM EDT Tiziana Life Sciences: Foralumab Update in Non-Active Secondary Progressive Multiple Sclerosis (na SPMS) Read More